31 results on '"Yel, Leman"'
Search Results
2. Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin deficiency
3. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies
4. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
5. Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease
6. Facilitated subcutaneous immunoglobulin 10% at a target dose of 0.4 g/kg/infusion is well tolerated with accelerated or no dose ramp-up in healthy participants
7. Tolerability and safety of facilitated subcutaneous immunoglobulin 20% in healthy adults: a phase 1 open-label study
8. Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USA
9. Corrigendum to “Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies” [Int. Immunopharmacol. 113(Part A) (2022) 109331]
10. Endonuclease G plays a role in immunoglobulin class switch DNA recombination by introducing double-strand breaks in switch regions
11. 10 - Molecular Biology and Genetic Engineering
12. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome
13. Characterization of naı̈ve, memory and effector CD8+ T cells: effect of age
14. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients With Immunodeficiencies Receiving Weekly Immune Globulin Subcutaneous [Human] 20% Solution (Ig20Gly)
15. List of Contributors
16. 10 - Molecular Biology and Genetic Engineering
17. Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in Patients With Primary Immunodeficiency Diseases: Interim Analysis of Adverse Events in a Global Post-Authorization Safety Study
18. Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency Diseases
19. Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies
20. A Registry Study on Treatment of Patients with Acquired Protein C Deficiency with a Protein C Concentrate (Human)
21. Treatment of Patients with Severe Congenital Protein C Deficiency in a Registry Study of Protein C Concentrate (Human)
22. Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over Time
23. Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America
24. Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies
25. Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)
26. Safety and Tolerability Of An Intravenously Administered Alpha1-Proteinase Inhibitor (A1PI) At An Increased Infusion Rate: A Randomized, Rate Control, Placebo-Masked, Crossover Study In Healthy Adults
27. Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs)
28. Contributors
29. Safety and Tolerability of an Intravenously-administered Alpha1-Proteinase Inhibitor (A1PI) at an Increased Infusion Rate: A Randomized, Placebo-Controlled, Phase 4 Study in Healthy Adults
30. Cellular immunodeficiency and autoimmunity in long-term mineral oil administration
31. Severe T- and B-cell immune deficiency associated with malignant thymoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.